Heron Therapeutics (HRTX) Change in Cash (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Change in Cash data on file, last reported at -$2.5 million in Q1 2026.

• Quarterly Change in Cash rose 61.27% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 679.85% YoY) and the FY2025 annual result came in at $2.8 million, up 198.96% from the prior year.
• Change in Cash rose to -$2.5 million in Q1 2026, from -$14.4 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $26.6 million in Q3 2025 to a low of -$35.1 million in Q4 2022.
• A 5-year average of -$3.8 million and a median of -$2.8 million in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash soared 1069.87% — and 2025, when it tumbled 23740.98%.
• Tracing HRTX's Change in Cash over 5 years: stood at -$35.1 million in 2022, then soared by 82.37% to -$6.2 million in 2023, then soared by 100.99% to $61000.0 in 2024, then plunged by 23740.98% to -$14.4 million in 2025, then soared by 82.46% to -$2.5 million in 2026.
• The last three Change in Cash figures came in at -$2.5 million (Q1 2026), -$14.4 million (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.